Although coronavirus disease 19 (COVID-19) most often affects the respiratory system, in the course of this disease, dysfunction of many other organs may also develop. The case is presented of a female patient, treated for a long time due to chronic obstructive pulmonary disease, complicated by chronic complete respiratory failure, and who was undergoing non-invasive mechanical ventilation at home. She was admitted to the Pneumonology Department due to exacerbation of the symptoms of her underlying disease. Several tests for SARS-CoV2 infection gave a negative result. During the patient’s stay in the clinic, a rapid increase was observed in symptoms of respiratory failure, heart failure, and laboratory signs of acute liver damage. The next PCR test result proved to be positive. In addition to the case report, the possible impact of SARS-CoV2 infection on liver damage is also also discussed, along with a literature review on this topic.
Gracia-Ramos AE, Jaquez-Quintana JO, Contreras-Omana R, et al. Liver dysfunction and SARS-CoV-2 infection. World J Gastroenterol. 2021; 27(26): 3951–3970.
Zou X, Fang M, Li S, et al. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol. 2021; 19(3): 597–603.
Chaibi S, Boussier J, Hajj WE, et al. Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort. Clin Res Hepatol Gastroenterol. 2020; 19: 101556.
Cichoż-Lach H, Michalak A. Liver injury in the era of COVID-19. World J Gastroenterol. 2021; 27(5): 377–390.
Pathikonda M, Munoz SJ. Acute liver failure. Ann Hepatol. 2010; 9(1): 7–14.
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. European Association for the Study of the Liver. J Hepatol. 2017; 66,5: 1047–1081.
Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure. The Lancet. 2010; 376(9736): 190–201.
Lin Y, Yuan J, Long Q, et al. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. Genes Dis. 2021; 8(4): 484–492.
Jaeschke H. Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients. Dig Dis. 2015; 33(4): 464–71.
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013; 369(26): 2525–34.
Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci. 2016; 17(2): 224.
Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol (NY). 2013; 9(9): 605–606.
Haque T, Sasatomi E, Hayashi PH. Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver. 2016; 10(1): 27–36.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases 2012. Levofloxacin. [Updated 2020 Mar 10]. Available from:
Paterson JM, Mamdani MM, Manno M, et al. Canadian Drug Safety and Effectiveness Research Network. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012; 184(14): 1565–1570.
Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011; 9(6): 517–523.e3.
Moreira JLS, Barbosa SMS, Gonçalves Júnior J. Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review. Clin Res Hepatol Gastroenterol. 2021; 23; 45(6): 101752.
Licata, A, Minissale, MG, Distefano, M, Montalto, G. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep. 2021; 3: 121–130.
Vitiello A, La Porta R, D’Aiuto V, et al. The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liv J. 2021; 11(1): 11.
Muhović D, Bojović J, Bulatović A, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020; 40(8): 1901–1905.
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020; 5; 383(19): 1827–1837. 10.1056/NEJMoa2015301.
Sweed D, Abdelsameea E, Khalifa EA et al. SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore. Egypt Liv J. 2021; 11: 64.
Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015; 13(2): 369–376.e3.
Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. World J Gastroenterol. 2020; 14; 26(46): 7272–7286.
Hiura M, Abe S, Tabaru A, et al. Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis. Hepatol Res. 2011; 41(5): 492–6. Epub 2011 Mar 21. PMID: 21435128.
Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015; 89(3): 327–34.
Kim T, Lee D, Lee JH, et al. Predictors of poor outcomes in patients with wild mushroom-induced acute liver injury. World J Gastroenterol. 2017; 21,23(7): 1262–1267.
Teschke R. Liver Injury by Carbon Tetrachloride Intoxication in 16 Patients Treated with Forced Ventilation to Accelerate Toxin Removal via the Lungs: A Clinical Report. Toxics. 2018; 6(2): 25.
Çagli K, Başar FN, Tok D, et al. How to interpret liver function tests in heart failure patients? Turk J Gastroenterol. 2015; 26(3): 197–203.
Nikolaou M, Mebazaa A. Cardiohepatic interactions in heart failure: clinical and therapeutical implications, Cont Cardiol Educ. 2017; 3(3).
Xanthopoulos A, Starling RC, Kitai T, et al. Heart Failure and Liver Disease: Cardiohepatic Interactions, JACC: Heart Failure. 2019; 7(2): 87–97.
Taylor RM, Tujios S, Jinjuvadia K, et al. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig Dis Sci. 2012; 57(3): 777–85.
Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020; 83(6): 521–523.].
Tian D, Ye Q. Hepatic complications of COVID-19 and its treatment. J Med Virol. 2020; 92(10): 1818–1824. https://10.1002/jmv.26036.
Mokhtari T, Hassani F, Ghaffari N, et al. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol. 2020; 51(6): 613–628. https://10.1007/s10735-020-099...].
Gurala D, Al Moussawi H, Philipose J, et al. Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease. Cureus. 2020; 26,12(8): e10045. https://10.7759/cureus.10045.
Samidoust P, Samidoust A, Samadani AA, et al. Risk of hepatic failure in COVID-19 patients. A systematic review and meta-analysis. Infez Med. 2020; 1; 28(suppl 1): 96–103.
Hundt MA, Deng Y, Ciarleglio MM, et al. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology. 2020; 72(4): 1169–1176. https://doi:10.1002/hep.31487.
Makarem J, Naghibi N, Beigmohammadi MT, et al. A Case Report of Progressive Liver Failure Inappropriate to Decompensated Heart Failure Following Infection With COVID-19. Cureus. 2020; 30; 12(8): e10142. https://10.7759/cureus.10142.
Ji D, Zhang D, Yang T, et al. Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020; 14(5): 701–710.
Khan MU, Mushtaq K, Alkaabi SR. Acute on Chronic Liver Failure – Possibly the main culprit of increased mortality in COVID-19 patients with liver disease. Gastroenterology. 2020; S0016-5085(20)34945-3.
Sarin SK, Choudhury A, Lau GK, et al. APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020; 14(5): 690–700.
Cameli M, Pastore MC, Soliman Aboumarie H, et al. Usefulness of echocardiography to detect cardiac involvement in COVID-19 patients. Echocardiography. 2020; 37(8): 1278–1286.
Schattenberg JM, Labenz C, Wörns MA, et al. Patterns of liver injury in COVID-19 – a German case series. United European Gastroenterol J. 2020; 8(7): 814–819.
Hamid S, Alvares da Silva MR, Burak KW, et al. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021; 55(1): 1–11.
Melquist S, Estepp K, Aleksandrovich Y, et al. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020; 99(43): e22818.
Kumar-M P, Mishra S, Jha DK. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int. 2020; 14(5): 711–722.
Fan Z, Chen L, Li J, et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020; 18(7): 1561–1566.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 588(7836): E6.
Pirisi M, Rigamonti C, D’Alfonso S, et al. Liver infection and COVID-19: the electron microscopy proof and revision of the literaturę. Eur Rev Med Pharmacol Sci. 2021; 25,4: 2146–2151.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280.e8.
Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United European Gastroenterol J. 2020; 8(5): 509–519.
Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. Bio-Rxiv 2020.
Chu H, Bai T, Chen L, et al. Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. Front Med (Lausanne). 2020; 7: 584342.
Kukla M, Skonieczna-Żydecka K, Kotfis K, et al. COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature. J Clin Med. 2020; 9(5): 1420.
Tian D, Ye Q. Hepatic complications of COVID-19 and its treatment. J Med Virol. 2020; 92(10): 1818–1824.
Nardo AD, Schneeweiss-Gleixner M, Bakail M, et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021; 41(1): 20–32.
Ferron PJ, Gicquel T, Mégarbane B, et al. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Biochimie. 2020; 179: 266–274.
Anirvan P, Bharali P, Gogoi M, et al. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome – what we know so far. World J Hepatol. 2020; 12(12): 1182–1197.
Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73: 807–816.
Da BL, Kushner T, El Halabi M, et al. Liver Injury in Hospitalized Patients with COVID-19 Correlates with Hyper Inflammatory Response and Elevated IL-6. Hepatol Commun. 2020; 16; 5(2): W177–88.